PPARG and type 2 diabetes mellitus: They are used as oral hypoglycemic agents to treat patients with type 2 diabetes mellitus (T2DM) and have the potential to limit the risk of developing brain injuries because PPARγ serves as a master regulator of cytoprotective stress responses [1].